## IQV: IQVIA Holdings Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.96 indicates fundamental undervaluation. Quality metrics strong (ROE 19%). Consistent execution (4/4 quarters beat estimates). Caution: declining volume (44% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($216.91)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Who Owns IQVIA Holdings? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20260102T220758 | Neutral | Relevance: 100%
- This article details the top shareholders of IQVIA Holdings (NYSE: IQVIA), highlighting major institutional investors like Vanguard and BlackRock, along with significant hedge fund activity. It also examines recent insider trades, noting a mix of sales and small director purchases. The overall analysis suggests that while IQVIA's ownership base is stable, there's varied sentiment among active managers regarding its valuation and short-term outlook.

**2. IQVIA’s Stock In Focus: Quiet Rally, Cautious Optimism And A Data-Driven Future**
- Source: AD HOC NEWS | 20260102T171843 | Bullish | Relevance: 100%
- IQVIA Holdings Inc. (IQV) has experienced a quiet rally, rewarding patient shareholders with modest gains and attracting cautiously optimistic attention from Wall Street analysts. The stock, which has steadily climbed towards its 52-week high, reflects a data-backed recovery despite a lack of dramatic news, underscoring its resilience as a proxy for biopharma R&D and healthcare digitalization. IQVIA's future performance hinges on its ability to secure new trial awards, convert AI/ML investments into efficiencies, and navigate broader economic factors, as it continues to deepen its competitive moat in data-driven healthcare.

**3. IQVIA’s Stock In Focus: Quiet Rally, Cautious Optimism And A Data-Driven Future**
- Source: AD HOC NEWS | 20260102T162035 | Bullish | Relevance: 100%
- IQVIA Holdings Inc's stock has shown a quiet rally, rewarding patient shareholders with modest gains, and is trading closer to its 52-week high. Wall Street analysts maintain a cautiously bullish stance, with price targets suggesting mid-teens upside. The company's future performance hinges on its ability to integrate clinical, commercial, and real-world data with AI, driven by new trial awards, analytics contracts, and macro factors.

**4. IQVIA’s Stock Finds Its Nerve: Can Data-Driven Healthcare Justify a Rich Valuation?**
- Source: AD HOC NEWS | 20260102T135956 | Bullish | Relevance: 100%
- IQVIA Holdings Inc. has seen its stock rise recently, demonstrating resilience amid regulatory scrutiny and high earnings expectations, leading to cautious optimism among investors. The company's performance over the past year shows low double-digit percentage gains and a relatively smooth ride through market fluctuations, positioning it as a high-quality compounder in the healthcare technology sector. Analysts generally view IQVIA positively, citing its durable revenue visibility and ability to convert vast data into higher-value software and decision support products as key drivers for continued growth.

**5. IQVIA’s Stock Finds Its Nerve: Can Data-Driven Healthcare Justify a Rich Valuation?**
- Source: AD HOC NEWS | 20260102T135808 | Bullish | Relevance: 100%
- IQVIA Holdings Inc has seen its stock quietly appreciate, fueled by a tech and healthcare rebound, and resilient fundamentals. Investors are now questioning whether the data and analytics specialist can sustain this performance and justify its premium valuation. The company's focus on integrating AI, navigating regulatory scrutiny, and its role in accelerating clinical trials are key factors influencing its future prospects.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 2 ($4.59M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Insider selling cluster: $4.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Insider selling cluster ($4.6M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.4B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.30 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 17.4 |
| Current P/E | 19.0 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 2.9pp (needs >4.0% for momentum thesis). MRS_5 at 0.2% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 54. Volume at 44% of 20MA suggests lack of conviction. OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.15% (CS: 56) | Neutral |
| RSI_14 | 53.9 | Neutral |
| MACD Histogram | -0.09 | Bearish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 1.017x | Above |
| vs SMA200 | 1.226x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $225.37
- **Stop Loss:** $216.91 (3.8% risk)
- **Target:** $242.29 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 170
- **Position Value:** $38,312.90
- **Portfolio %:** 38.31%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*